BMY News | Roxom Stocks

1 BTC

=

- USD

Loading market data...

BM

Mkt Cap

$128.81B

Volume

9.26M

Next Earnings

October 29th

Chart Financials Earnings News About Dividends Insider Filings

Wall Street's Bull Case for Bristol Myers Squibb Is Getting LouderBristol Myers Squibb (BMY) is up 17% this year and trades at a discount to peers despite strong Q2 performance with $12.9B revenue and 153% EPS growth. The company's growth portfolio of newer drugs now accounts for nearly 60% of revenue and grew 15% year-over-year, offsetting concerns about patent expirations on legacy drugs. With a 3.95% dividend yield, $5B buyback program, and potential acquisition interest from AstraZeneca, analysts see significant upside potential as the market has underpriced the stock relative to its pipeline execution.The Motley Fool · Sep 20, 2026

Can Sotyktu's Long-Term PsA Data Boost Bristol Myers' Prospects?Bristol Myers announced positive two-year results from the POETYK PsA-2 study showing Sotyktu (deucravacitinib) maintained durable efficacy and consistent safety through week 104. The drug generated $156 million in H1 2026 revenues, up 24% year-over-year, with potential for further expansion into lupus and Sjögren's disease indications.Zacks Investment Research · Sep 18, 2026

BMY vs. ARGX: Which Stock Is the Better Value Option?Bristol Myers Squibb (BMY) is positioned as a superior value opportunity compared to Argenex SE (ARGX) in the biomedical and genetics sector. BMY has a Zacks Rank of #2 (Buy) with a forward P/E of 9.10 and Value grade of A, while ARGX has a Zacks Rank of #3 (Hold) with a forward P/E of 34.19 and Value grade of C. BMY's lower valuation metrics and stronger earnings outlook make it the more attractive value play.Zacks Investment Research · Sep 18, 2026

AbbVie vs. Bristol Myers Squibb: Which Healthcare Stock Is a Better Buy in 2026?AbbVie and Bristol Myers Squibb are compared as pharmaceutical investment options for 2026. AbbVie is recommended as the better buy due to its successful immunology franchise with Skyrizi and Rinvoq driving growth, diversification into aesthetics and neuroscience, and having navigated its patent cliff challenges. Bristol Myers Squibb, while cheaper on valuation metrics and maintaining strong profit margins, faces revenue stagnation, legal uncertainties from a Celgene acquisition lawsuit, and is still working through its own portfolio transition challenges.The Motley Fool · Sep 18, 2026

Improve Your Retirement Income with These 3 Top-Ranked Dividend StocksWith traditional retirement income sources like bonds and Social Security proving inadequate, the article recommends dividend-paying stocks from high-quality companies as a reliable income alternative. Three stocks are highlighted: Bristol Myers Squibb (3.96% yield), Fulton Financial (3.24% yield), and InvenTrust Properties Corp. (3.24% yield), all offering steady dividend growth to help offset inflation.Zacks Investment Research · Sep 17, 2026

Autoimmune Disease Therapeutics Market Set for Growth Through 2034 as Biologics, Precision Medicine and Pipeline Innovation Reshape the Competitive LandscapeThe global autoimmune disease therapeutics market is projected to grow from USD 132.75 billion in 2025 to USD 254.60 billion by 2034, at a CAGR of 7.5%. Growth is driven by rising autoimmune disease diagnoses, increased adoption of biologics and targeted oral therapies, biosimilar expansion, and emerging cell and gene therapies. Biologics dominate with 66% market share, TNF inhibitors lead drug classes at 29%, and rheumatoid arthritis accounts for 34% of revenue. North America holds 44% regional share while Asia-Pacific is expected to grow fastest.GlobeNewswire Inc. · Sep 17, 2026

CAR T-Cell Therapy for Non-Hodgkin’s Lymphoma Market Set for Expansion Through 2036, Fueled by Treatment Innovation and Rising Patient DemandThe CAR T-cell therapy market for non-Hodgkin's lymphoma is projected to grow at a 7% CAGR from 2026 to 2036, reaching from a 2025 valuation of $3.20 billion across seven major markets. Growth is driven by broader clinical adoption, new indications, earlier-line use, and innovation in autologous and allogeneic platforms. The U.S. dominates with $1.90 billion in 2025 market value, while diffuse large B-cell lymphoma represents the largest patient population with approximately 78,000 cases across the markets.GlobeNewswire Inc. · Sep 16, 2026

Immunotherapy Drugs Market 2026: Precision Medicine, Next-Generation Biologics and Expanding Cancer Indications Fuel Growth OpportunitiesThe global immunotherapy drugs market is experiencing significant growth driven by advances in biotechnology, rising demand for targeted treatments, and expanding therapeutic applications across cancer, autoimmune, and inflammatory diseases. Key growth factors include increasing disease burden, robust drug pipelines, personalized medicine adoption, and combination therapy development. The Americas and Europe remain dominant markets, while Asia-Pacific is emerging as a high-growth region. Major pharmaceutical and biotech companies are increasing R&D investments and collaboration to accelerate innovation.GlobeNewswire Inc. · Sep 15, 2026

Should You Invest in the iShares U.S. Pharmaceuticals ETF (IHE)?The iShares U.S. Pharmaceuticals ETF (IHE) is a passively managed fund offering broad exposure to the Healthcare-Pharma sector with $1.63 billion in assets. The ETF has delivered strong year-to-date returns of 20.69% and 45.67% over the past year, though it carries higher risk with a beta of 0.49 and standard deviation of 16.8%. It holds approximately 60 pharmaceutical companies with top holdings including Johnson & Johnson (22.21%), Eli Lilly, and Bristol Myers Squibb, and carries a Zacks ETF Rank of 3 (Hold).Zacks Investment Research · Sep 15, 2026

MRK Banks on Growing Pipeline & New Drugs to Offset Keytruda LOEMerck is preparing for the 2028 loss of exclusivity for its blockbuster cancer drug Keytruda by significantly expanding its drug pipeline. The company's phase III pipeline has nearly tripled since 2021, with 20 new drugs expected by 2030 and over $70 billion in potential pipeline opportunity by the mid-2030s. Emerging growth drivers include Winrevair, Capvaxive, and Welireg, positioning Merck for continued growth despite Keytruda's anticipated sales decline once biosimilars enter the market.Zacks Investment Research · Sep 11, 2026

BM

BMYBristol-Myers Squibb Co.

BMY

Pay with—

Available Balance0.00

Your PositionYou don't own any BMY yet.

Related Tickers

Earnings

Dividends

Ex Oct 2

Amount$0.63

PaysNov 2

Last · Jul 2Quarterly

Amount$0.63

Yield4.00%

Annual$2.52